Fractyl Health (GUTS) - Company Revenue

Fractyl Health, Inc. (GUTS) is developing innovative endoscopic and gene therapies to combat obesity and diabetes. The company's sales time series on GURU.Markets reflects current demand, where the 0.00 mark captures this metric. The business is shielded from macroeconomic shocks due to the specific nature of medicine, although financial stability currently relies entirely on external research investments.

GUTS Fractyl Health, Inc: Company Revenue in the range 02/21/2024 - 11/15/2026

Analytical breakdowns for Fractyl Health, Inc.

- price and consensus price forecast:

Stock Price Fractyl Health, Inc.|GUTS - Analyst Consensus Forecast

- market capitalization indicators:

Market Value Fractyl|GUTS - Total Company Value

- book capitalization information:

Net Asset Value per Share Fractyl Health|GUTS - Company Book Value|Market Value to Book Value Ratio fractyl.com|GUTS - Company Total Assets

- company liabilities and liquidity data:

- business earnings and investment ratios data:

GUTS - Net Profit|Projected Future Earnings Fractyl Health, Inc.|GUTS - P/E Multiple|Projected Price to Earnings Fractyl|GUTS - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Fractyl Health, Inc|GUTS - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months Fractyl Health|GUTS - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months fractyl.com|GUTS - Net earnings per share growth this year|Expected earnings per share trend next year Fractyl Health, Inc.

- sales volume and revenue indicators:

GUTS - Revenue and Sales Volume|Company Future Revenue Fractyl Health, Inc.|GUTS - P/S Multiple|Market Cap to Future Revenue Ratio Fractyl Health Inc.|GUTS - Sales Growth YoY (TTM)

Comprehensive company analysis:GUTS Fractyl Health, Inc.

Investors seek an equilibrium point between an asset's market value and its intrinsic quality. This indicator aggregates daily sales revenue, allowing for an assessment of the business's real operational efficiency relative to historical values. For Fractyl Health, Inc. (GUTS), this reflects the commercial success of implementing innovative therapies for diabetes and obesity. By analyzing the company's current sales volume, one can determine the resilience of its fundamental metrics against inflationary pressure.

Key competitors